Home / Health / Kids' Weight Crisis: GLP-1s Show Promise, But Questions Linger
Kids' Weight Crisis: GLP-1s Show Promise, But Questions Linger
22 Jun
Summary
- Obesity affects 21% of U.S. children and teens, a significant rise since the 1970s.
- GLP-1 medications show transformative results in some severely obese children.
- Approved for older adolescents, these drugs are being tested in younger children.
Obesity in U.S. children and teens has reached 21%, a dramatic increase from approximately 5% in the 1970s. Doctors are increasingly prescribing GLP-1 medications for severe pediatric obesity, reporting transformative outcomes and significant BMI reductions in young patients. These drugs, like Novo Nordisk's Wegovy and Saxenda, are approved for adolescents aged 12 and older for obesity treatment.
While the long-term effects of GLP-1s in children are still unknown, physicians emphasize the severe health risks associated with childhood obesity, including premature mortality and reduced quality of life. The medications are also being tested in children as young as six, with companies like Eli Lilly studying their own obesity drugs in younger age groups.
One case highlights the challenges parents face, with twins showing extreme hunger and rapidly increasing BMIs despite lifestyle interventions. After a genetic mutation affecting appetite perception was identified, and other treatments proved insufficient, parents inquired about GLP-1s for their sons, who were seven years old at the time.
